Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) – Pipeline Review, H1 2019

Global Markets Direct’s, ‘Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) – Pipeline Review, H1 2019’, provides in depth analysis on Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology and Non Malignant Disorders under development targeting Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)

– The report reviews Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Akshaya Bio Inc

Bavarian Nordic A/S

Boehringer Ingelheim GmbH

Etubics Corp

GeoVax Labs Inc

Merck KGaA

Minerva Biotechnologies Corp

NantKwest Inc

Peptron Inc

Transgene SA

Vaxil Bio Therapeutics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) Overview

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) Companies Involved in Therapeutics Development

Akshaya Bio Inc

Bavarian Nordic A/S

Boehringer Ingelheim GmbH

Etubics Corp

GeoVax Labs Inc

Merck KGaA

Minerva Biotechnologies Corp

NantKwest Inc

Peptron Inc

Transgene SA

Vaxil Bio Therapeutics Ltd

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) Drug Profiles

BI-1361849 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-301 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-051 + ETBX-061 + ETBX-011 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target MUC1 for Gastric Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GEOCM-01 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GI-6108 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GO-2032c Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ImMucin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mesmulogene ancovacivec Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit MUC1 for Breast Cancer and Pancreatic Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit MUC1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit MUC1 for Metastatic Breast Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tecemotide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Brachyury Protein, KLK3 and MUC1 for Castration Resistant Prostate Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC-1 and TLR-2 for Breast Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Mucin 1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccines to Target MUC1 for Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) Dormant Products

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) Discontinued Products

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) Product Development Milestones

Featured News & Press Releases

Mar 12, 2019: GeoVax selected as finalist for Vaccine Industry Excellence Awards

Nov 02, 2018: Bavarian Nordic announces initiation of clinical trial evaluating the combination therapy of CV301 and Durvalumab in metastatic colorectal and pancreatic cancers

Sep 20, 2018: Bavarian doses first patient in CV301 and atezolizumab Phase ll trial

Aug 10, 2018: HCRN study explores investigational vaccine therapy for metastatic colorectal cancer

Jul 11, 2018: Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

Jun 19, 2018: Exploring a New Treatment for Metastatic Colorectal Cancer

May 03, 2018: Israeli Cancer Research Firm Vaxil Granted 9th Patent for Immunotherapy Treatment

Mar 08, 2018: Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer

Jan 16, 2018: First Patient Dosed in a Phase 2 Trial with Transgene TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)

Oct 30, 2017: Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017

Oct 12, 2017: Peer Reviewed Scientific Publications Highlight TG4010's Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors

Oct 09, 2017: GeoVax Chief Scientific Officer to Deliver Two Talks at World Vaccine Congress

Sep 11, 2017: Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer

Aug 30, 2017: GeoVax Presents Preliminary Data for Cancer Vaccine

Jul 24, 2017: Cancer Immunotherapy Company Vaxil Appoints Dr. Terry Plasse as Chief Medical Officer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by Akshaya Bio Inc, H1 2019

Pipeline by Bavarian Nordic A/S, H1 2019

Pipeline by Boehringer Ingelheim GmbH, H1 2019

Pipeline by Etubics Corp, H1 2019

Pipeline by GeoVax Labs Inc, H1 2019

Pipeline by Merck KGaA, H1 2019

Pipeline by Minerva Biotechnologies Corp, H1 2019

Pipeline by NantKwest Inc, H1 2019

Pipeline by Peptron Inc, H1 2019

Pipeline by Transgene SA, H1 2019

Pipeline by Vaxil Bio Therapeutics Ltd, H1 2019

Dormant Products, H1 2019

Dormant Products, H1 2019 (Contd..1), H1 2019

Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports